Supplying medication to a third party

Key considerations and a recommended course of action when a pharmacist is asked to supply medication to a third party. Scenario: A 20-year-old man approaches a...

Changes to injectable weight loss medicines

The landscape for glucagon-like peptide-1 receptor agonists (GLP-1RAs) used for weight loss is changing in Australia as demand continues to grow.

Helping patients understand new vaping restrictions

With additional vaping restrictions rolling out throughout 2024, more patients will likely seek therapeutic vaping products.

How to identify the most accurate RATs

Find out which COVID-19 rapid antigen tests are the best-performing, and what product has failed to detect the virus.

TGA issues two new safety alerts for GLP-1 RA products

The Therapeutic Goods Administration (TGA) has today (Monday 1 December) made updates to product warnings for GLP-1 and dual GIP/GLP-1 receptor agonists for two...

Supporting patients through GLP-1 agonist cessation effects

Glucagon-like peptide 1 (GLP-1) agonists, traditionally used to manage type 2 diabetes, have been increasingly prescribed off-label for weight loss.  There are four GLP-1 agonist...